CSPC PHARMA SYH2056 tablets approved to start clinical trials

AASTOCKS
2025.11.23 11:36

CSPC PHARMA (01093.HK) announced that the Group's developed chemical drug Class 1 new drug selective 5-hydroxytryptamine 2A receptor "5-HT2A receptor" agonist (SYH2056 tablets) has been approved by the National Medical Products Administration of China to conduct clinical trials in China. The approved clinical indication is for the treatment of depression

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer